

Sanofi  
Form 6-K  
November 06, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of November 2015**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

## Edgar Filing: Sanofi - Form 6-K

In November 2015, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.4 which are incorporated herein by reference.

### Exhibit List

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated November 6, 2015: Sanofi Sets Out Strategic Roadmap for Long-term Growth
Exhibit 99.2	Press release dated November 6, 2015: Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
Exhibit 99.3	Press release dated November 5, 2015: Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
Exhibit 99.4	Press release dated November 3, 2015: Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 6, 2015

SANOFI

By  
Name:  
Title:

/s/ John Felitti  
John Felitti  
Associate Vice President,  
Corporate Law, Financial &  
Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated November 6, 2015: Sanofi Sets Out Strategic Roadmap for Long-term Growth
Exhibit 99.2	Press release dated November 6, 2015: Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
Exhibit 99.3	Press release dated November 5, 2015: Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
Exhibit 99.4	Press release dated November 3, 2015: Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement